In This Article:
Editas Medicine (NASDAQ:EDIT) First Quarter 2025 Results
Key Financial Results
-
Revenue: US$4.66m (up 310% from 1Q 2024).
-
Net loss: US$76.1m (loss widened by 23% from 1Q 2024).
-
US$0.92 loss per share (further deteriorated from US$0.76 loss in 1Q 2024).
Our free stock report includes 2 warning signs investors should be aware of before investing in Editas Medicine. Read for free now.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Editas Medicine Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates significantly. Earnings per share (EPS) missed analyst estimates by 60%.
Looking ahead, revenue is expected to decline by 36% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 17%.
Performance of the American Biotechs industry.
The company's shares are up 13% from a week ago.
Risk Analysis
Before you take the next step you should know about the 2 warning signs for Editas Medicine (1 doesn't sit too well with us!) that we have uncovered.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.